Additionally, we examined the impact of ponatinib (AP24534), a pan-BCR-ABL kinase inhibitor approved for treating chronic myeloid leukemia and Philadelphia chromosome–positive acute lymphoblastic leukemia. The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.